Oligosaccharide riclinoctaose is used in preparation of a drug for treating and/or preventing ischemia-reperfusion injury (IRI). The oligosaccharide riclinoctaose has a structural formula as follows:

##STR00001##

The oligosaccharide riclinoctaose can significantly relieve postoperative liver injury, kidney injury, and brain injury in ischemia-reperfusion mice.

Oligosaccharide riclinoctaose is used in preparation of a drug for treating and/or preventing ischemia-reperfusion injury (IRI). The oligosaccharide riclinoctaose has a structural formula as follows:

##STR00001##

The oligosaccharide riclinoctaose can significantly relieve postoperative liver injury, kidney injury, and brain injury in ischemia-reperfusion mice.

The present invention relates to a multi-postbiotics-compounded rejuvenating essence, which includes the following components in percentage by weight: 8.0-13.0% of butanediol, 2.0-3.0% of triglyceride octoate/caprate/succinate, 2.0-3.0% of polyglutamate sodium, 0.5-1.0% of extract of Japanese Ardisia herb stems, 0.5-1.0% of yeast/rice ferment filtrate, 0.5-1.0% of fission yeast mycelium ferment filtrate, 0.5-1.0% of lactobacillus/mung bean extract/sodium glutamate ferment filtrate, 0.5-1.0% of lactobacillus ferment, 0.5-1.0% of bacillus/rice bran extract/soybean extract ferment filtrate, 0.5-1.0% of Streptococcus thermophilus ferment, 0.1-0.2% of collargol, and 65.3-79.4% of deionized water, wherein the essence is put in an airtight container and is injected with hydrogen. The present invention can achieve an effect of repairing the skin, and the combination of active substances with the hydrogen injected has a prominent effect on reducing the amount of allergic erythema and alleviating the recurrent allergic redness and rashes.

The present invention relates to a multi-postbiotics-compounded rejuvenating essence, which includes the following components in percentage by weight: 8.0-13.0% of butanediol, 2.0-3.0% of triglyceride octoate/caprate/succinate, 2.0-3.0% of polyglutamate sodium, 0.5-1.0% of extract of Japanese Ardisia herb stems, 0.5-1.0% of yeast/rice ferment filtrate, 0.5-1.0% of fission yeast mycelium ferment filtrate, 0.5-1.0% of lactobacillus/mung bean extract/sodium glutamate ferment filtrate, 0.5-1.0% of lactobacillus ferment, 0.5-1.0% of bacillus/rice bran extract/soybean extract ferment filtrate, 0.5-1.0% of Streptococcus thermophilus ferment, 0.1-0.2% of collargol, and 65.3-79.4% of deionized water, wherein the essence is put in an airtight container and is injected with hydrogen. The present invention can achieve an effect of repairing the skin, and the combination of active substances with the hydrogen injected has a prominent effect on reducing the amount of allergic erythema and alleviating the recurrent allergic redness and rashes.

The present invention relates to the identification of a group of microorganisms, which are relatively abundant in the microbial communities associated with fruits and vegetables typically consumed raw and therefore transient or permanent members of the human microbiota. These microbes are used to augment the effects of additional probiotic strains. The consumption of mixtures of these microbes at relevant doses will produce a beneficial effect in the host mediated in part by production of short chain fatty acids to enhance colonic butyrate production. Therapeutic methods of the invention involve the use of live microorganisms or metabolites derived from said microorganisms to establish a microbial composition in the mammalian host that will provide a health benefit to a mammal in need thereof.

The present invention relates to the identification of a group of microorganisms, which are relatively abundant in the microbial communities associated with fruits and vegetables typically consumed raw and therefore transient or permanent members of the human microbiota. These microbes are used to augment the effects of additional probiotic strains. The consumption of mixtures of these microbes at relevant doses will produce a beneficial effect in the host mediated in part by production of short chain fatty acids to enhance colonic butyrate production. Therapeutic methods of the invention involve the use of live microorganisms or metabolites derived from said microorganisms to establish a microbial composition in the mammalian host that will provide a health benefit to a mammal in need thereof.

The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

A citrine pleurotus (Pleurotus citrinopileatus) polysaccharide and application thereof are provided, which relate to the field of natural product development and utilization. The citrine pleurotus polysaccharide includes xylose, glucose, galactose, glucuronic acid, fucose, fructose and arabinose. The citrine pleurotus polysaccharide can be applied in preparing drugs for treating sarcopenia caused by cancers. It is demonstrated that the polysaccharide of citrine pleurotus may increase a body weight and a spleen weight, restore morphology, number and density of muscle fibers, reduce inflammatory response and decrease expressions of signature proteins of Atrogin-1 and MuRF-1 for sarcopenia, and alleviate symptoms of tumor-induced sarcopenia in mice with colon cancer cachexia. New effects of polysaccharides of citrine pleurotus are discovered, which provides new ideas for exploitating the citrine pleurotus and treating the sarcopenia caused by cancers.

A citrine pleurotus (Pleurotus citrinopileatus) polysaccharide and application thereof are provided, which relate to the field of natural product development and utilization. The citrine pleurotus polysaccharide includes xylose, glucose, galactose, glucuronic acid, fucose, fructose and arabinose. The citrine pleurotus polysaccharide can be applied in preparing drugs for treating sarcopenia caused by cancers. It is demonstrated that the polysaccharide of citrine pleurotus may increase a body weight and a spleen weight, restore morphology, number and density of muscle fibers, reduce inflammatory response and decrease expressions of signature proteins of Atrogin-1 and MuRF-1 for sarcopenia, and alleviate symptoms of tumor-induced sarcopenia in mice with colon cancer cachexia. New effects of polysaccharides of citrine pleurotus are discovered, which provides new ideas for exploitating the citrine pleurotus and treating the sarcopenia caused by cancers.

A composition comprising, as an active ingredient, a cell body of a fig-derived lactic acid bacterium belonging to Lactobacillus paracasei, a cultured or fermented product thereof, or a polysaccharide produced thereby is effective in improving, preventing or treating an inflammatory bowel disease and can be particularly used as a food or drink, a medicament or a feed for improving, preventing or treating ulcerative colitis or Crohn's disease.